Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.44 |
| ▸ | ESRRB | O95718 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESRRA | P11474 | 1/20 | 0.42 |
| ▸ | ESRRG | P62508 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486767 | 0.90 | GPR119 (0.58) | GPR119 | |
| SCHEMBL24847031 | 0.87 | MAPT (0.56) | ALDH1A1LMNAMAPTGPR119ESRRB | |
| SCHEMBL24091408 | 0.86 | EGLN2 (0.54) | EGLN2ALDH1A1LMNAMAPTGPR119 | |
| SCHEMBL24091363 | 0.86 | EGLN2 (0.54) | EGLN2ALDH1A1LMNAMAPTKCNH2 | |
| SCHEMBL30976319 | 0.85 | EGLN2 (0.53) | EGLN2ALDH1A1LMNAMAPTKCNH2 | |
| SCHEMBL24847034 | 0.84 | MAPT (0.44) | EGLN2ALDH1A1LMNAMAPTKCNH2 | |
| SCHEMBL30180270 | 0.84 | MAPT (0.44) | EGLN2ALDH1A1LMNAMAPTKCNH2 | |
| SCHEMBL19001559 | 0.82 | MAPT (0.51) | ALDH1A1LMNAMAPTGPR119ESRRB | |
| SCHEMBL30930919 | 0.82 | MAPT (0.51) | ALDH1A1LMNAMAPTGPR119ESRRB | |
| SCHEMBL688078 | 0.81 | GPR119 (0.56) | EGLN2ALDH1A1LMNAMAPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-12162870-B2 | Anticancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4351560-A1 | ANTICANCER COMPOUNDS | The Regents of the University of California (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117794525-A | Anticancer compounds | 加利福尼亚大学董事会 | 2024-03-29 | — | — | CN | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| WO-2023278759-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-8530480-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-05 | — | — | US | disclosed |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2200436-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | The Scripps Research Institute (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009032861-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032861-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | EGLN2 2570/4885ALDH1A1 2904/4885LMNA 4560/4885 |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | EGLN2 3886/4885ALDH1A1 3346/4885LMNA 4337/4885 |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | EGLN2 3886/4885ALDH1A1 3346/4885LMNA 4337/4885 |
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | EGLN2 1971/4885ALDH1A1 4097/4885LMNA 3037/4885 |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | EGLN2 1971/4885ALDH1A1 4097/4885LMNA 3037/4885 |
| US-12162870-B2 | Anticancer compounds | BET1, BRD4, BICRA | EGLN2 3886/4885ALDH1A1 3346/4885LMNA 4337/4885 |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | EGLN2 2570/4885ALDH1A1 2904/4885LMNA 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.